There are a lot of solutions and substitutes in the market to help smokers quit. However, each person has their own unique way of responding to them depending on their genetic makeup. Gene testing can help determine which method can work best for each individual.
For instance, a research paper published in Biological Psychiatry tried to assess when bupropion — one of only two non-nicotine smoking-cessation drugs approved by the Food and Drug Administration (FDA) in the US — would be effective for a particular person. It showed that 55% of people of European descent with the CYP2b6*1 gene variation showed no added benefit. However, about 30% of people within the group quit smoking regardless of whether they were taking the drug or the placebo.
Individuals with the CYP2B6*6 mutation had a harder time quitting, but showed greater benefit from taking the drug as compared to the placebo. These tests are nowhere near being in the mainstream right now, however, the information can a long way to prove which smoking-cessation drugs are useful and how to develop them to be more efficient in the future.
I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
One of the world's only 5-star airlines seems to be considering asking business-class passengers to bring their own cutlery
Vodafone Idea FPO allotment – How to check allotment, GMP and more
Vodafone Idea shares jump nearly 8%
Indians can now get multiple entry Schengen visa with longer validity as EU eases norms
Investing Guide: Building an aggressive portfolio with Special Situation Funds
Next Story